الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 76 |  |  |
| | | from | 76 | | |
Abstract
Primary Lung cancers are divided into non–small cell carcinoma (NSCC) and small cell carcinoma (small cell lung carcinoma, SCLC), with the former accounting for 80% of the cases and the latter accounting for the remaining 20%.
Surgical resection remains the mainstay of treatment for all patients with stage I and II NSCLC with no evidence of mediastinal disease or invasion of local organs.
The ultimate goal of this research was to evaluate the technical feasibility and limitations of video-assisted mediastinoscopic lymphadenectomy (VAMLA) followed by video-assisted thoracoscopic surgery (VATS) lobectomy and video-assisted thoracoscopic surgery (VATS) lobectomy alone in treating patients with non-small cell lung cancer.
Between September 2015 and September 2016 twenty-two non-small cell lung cancer patients admitted to the Department of Thoracic Surgery of the Referral Oncologic Center of Basilicata (IRCCS-CROB), Italy, were studied.
Six patients underwent a combination of subsequent VAMLA and VATS lobectomy (group A), whereas sixteen patients underwent lobectomy and mediastinal lymphadenectomy using thoracoscopy only (group B).
Comparison between the two studied groups was done regarding the baseline characteristics, operative profiles and complications.
In our study, males were more than females (17 patients vs. 5 patients) respectively. The most common operated tumour was T1 (18 patients). And, the most common encountered tumour histology type was adenocarcinoma (17 Patients).
Our results highlighted that the lobectomy median operative time was shorter in (group A), (117 minutes) compared to (group B), (157.5 minutes). Furthermore, the median total number of mediastinal lymph nodes excised in (group A), (18 lymph nodes) was more than (group B), (12.5 lymph nodes).
These results were discussed and compared to other series in the medical literature regarding the evaluation of the technical feasibility and limitations of video-assisted mediastinoscopic lymphadenectomy (VAMLA) followed by video-assisted thoracoscopic surgery (VATS) lobectomy and video-assisted thoracoscopic surgery (VATS) lobectomy alone in treating patients with non-small cell lung cancer.